Review summary
Consumer version
About this resource
Publication date:
Publication type:
Report
Language:
English
Australian Government Department of Health, Disability and Ageing
Elosulfase alfa 24 month-like review
This 24 month-like review aimed to ensure that the listing of elosulfase alfa for the treatment of MPS IVA on the LSDP remains appropriate. It was considered by the Expert Panel at its October 2022 and February 2023 meetings.